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Abstract. The journey patients with ovarian cancer travel from 
non-specific symptoms causing delayed diagnosis through 
surgery and chemotherapy, culminating in a 5-year survival 
rate of 43%, must have a profound and detrimental psycho-
logical impact on patients. Emerging studies link higher levels 
of oxytocin (OT) and increased social support, an indepen-
dent prognostic factor in cancer, with a moderating effect on 
stress. In contrast, there is a known association of tumour cell 
proliferation with elevated cortisol (stress hormone) levels. We 
hypothesise therefore that there is cross-talk between cortisol 
and oxytocin at a molecular level. Three ovarian cancer cell 
lines, used as in vitro models, were treated with cortisol at 
concentrations mimicking physiological stress in vivo in the 
presence or absence of OT. OT reduced cell proliferation and 
migration, induced apoptosis and autophagy for all three cell 
lines, partially reversing the effects of cortisol. Quantitative 
RT-PCR of tissue taken from ovarian cancer patients revealed 
that the glucocorticoid receptor (splice variant GR-P) and OT 
receptor (OTR) were significantly upregulated compared to 
controls. Tissue microarray revealed that the expression of 
GRα was lower in the ovarian cancer samples compared to 
normal tissue. OT is also shown to drive alternative splicing 
of the GR gene and cortisol-induced OTR expression. OT 
was able to transactivate GR in the presence of cortisol, 
thus providing further evidence of cross-talk in vitro. These 
data provide explanations for why social support might help 
distressed ovarian cancer patients and help define novel 
hypotheses regarding potential therapeutic interventions in 
socially isolated patients.
Introduction
Stress responses and related psychosocial factors (e.g., hope-
lessness and social support) can be of significant prognostic 
value for cancer progression (1). Stress is defined as ‘the state 
of threatened or perceived as threatened homeostasis, associ-
ated with activation of the stress system, mainly comprised 
by the hypothalamic-pituitary-adrenal axis and the arousal/
sympathetic nervous systems’ (2). Widely accepted as being a 
complex construct, stress, is divided into several stages: i) the 
stressors which are the event potentially leading to the psycho-
physiological features associated with stress, ii) the mediators 
which can involve the appraisal of, as well as coping with, 
the stressor, iii) the moderators where this can include the 
social support being available as well as the personality and 
resource of the individual, and finally, iv) the stress response 
itself which includes activation of the hypothalamic-pituitary-
adrenal (HPA) axis and the sympathetic nervous system (3-6). 
The physiological response to stress usually involves activation 
of the HPA axis above the basal level, resulting in increased 
synthesis and secretion of glucocorticoids (GC) (such as 
cortisol) as well as activation of the sympathetic nervous system 
resulting in the secretion of catecholamines (such as adrenalin) 
(7). Concerning cancer prognosis, certain psychosocial factors 
such as little social support and hopelessness were found in 
many prospective studies and reviews to predict prognosis in 
cancer, independent of confounders such as cancer stage and 
treatments (1,8,9). Such responses are thought to partly affect 
cancer progression via the effects of glucocorticoids on cancer 
cells. Several studies have found that cortisol administration 
leads to greater cell invasiveness in some cancer cell lines (10).
Cortisol exerts its actions by binding to and activating 
glucocorticoid receptors (11,12). The glucocorticoid receptor 
(GR) is a nuclear receptor that acts as a phosphoprotein and a 
transcription factor modulating transcriptional events. To date, 
the cloning of four splice variants of the GR gene have been 
reported: GRα, GRβ, GRγ and GR-P (13). Moreover, growth 
arrest-specific transcript 5 (GAS5) encodes a single strand 
non-coding RNA (ncRNA). GAS5 ncRNA can be a repressor 
for the GR by acting as a decoy glucocorticoid response 
element (GRE), competing with DNA GREs for binding to 
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the GR. GAS5 ncRNA thus acts as a negative regulator by 
preventing GRs from binding to their DNA GRE and compro-
mising the normal functions of the GR-cortisol complex (14).
Abnormal regulation of the immune system by stressors, 
whether suppression of anticancer cellular immunity or 
enhancement of pro-inflammatory cytokines (15,16) may 
result in significant adverse health consequences for tumour 
proliferation and metastatic events (17). In addition, patients 
diagnosed with cancer face psychosocial stressors that can 
lead to abnormal levels of cortisol (18). Indeed, nocturnal 
cortisol and cortisol variability show significant dysregulation 
in ovarian cancer patients, and this dysregulation is associ-
ated with greater functional disability, fatigue, and vegetative 
depression (19). In some other cancers, little cortisol variability 
was also found to predict poor prognosis (20).
The neurohormone OT is involved in various aspects of 
social cognition and prosocial behaviour such as trust (21,22). 
Central OT exerts anxiolytic and anti-depressive effects by 
activating its cognate receptor OTR which belongs to the 
GPCR superfamily (23). Early studies in a rodent model have 
shown that oxytocin decreases blood pressure and lowers 
circulating cortisol levels (24). Intranasal OT benefits some 
aspects of socio-emotional functioning (21). Furthermore, one 
study found that OT also interacts synergistically with social 
support in relation to cortisol secretion: during stress, people 
who received both OT and social support had lower cortisol 
levels than those receiving either treatment alone or no treat-
ment (25). A number of studies proposed that OT can act as a 
negative regulator of cell proliferation in human breast carci-
nomas (26), human central nervous system tumours (27), and 
human osteosarcoma cell lines (28). Human endometrial carci-
nomas also express OTR, and OT inhibits the proliferation of 
endometrial cancer cells (29). Intraperitoneal administration 
of OT resulted in the reduction of intraperitoneal dissemina-
tion of ovarian carcinoma cells in a mouse model (30). Thus, 
there is regulatory cross-talk between OT and cortisol both at 
the socio-behavioural and at the systemic levels, which may 
also have consequences at the tumour level.
However, to this date, little is known about potential cross-talk 
between cortisol and oxytocin in the context of cancer in general 
and in ovarian cancer specifically. Because of the often grave 
prognosis of ovarian cancer due to it being diagnosed frequently 
at advanced stages (31), and since it is easy to administer OT, it 
seemed important to examine the effects of OT and cortisol on 
ovarian cancer cells first in vitro. Based on their opposing effects, 
we hypothesised that the activity of cortisol in ovarian cancer 
cells might be compromised if OTR signalling is activated.
Materials and methods
Patients. Clinical samples were of ovarian origin (n=12) and 
were taken from patients admitted to the First Department of 
Obstetrics and Gynecology, Papageorgiou General Hospital, 
Medical School, Aristotle University, Thessaloniki, Greece. 
Ethical approval was obtained by the local authority and Brunel 
University. The majority of ovarian cancers were deemed to be 
grade 3 stage III (poorly differentiated and involving the whole 
peritoneal cavity, not just confined to ovaries/tubes or pelvis) 
(10/12). Control samples (n=10) were also used in this study, 
obtained from patients undergoing total hysterectomy and 
bilateral salpingo-oopherectomy for benign reasons. None of 
the two groups (ovarian cancer and control) received hormone 
replacement therapy, and ovarian cancer patients were all post-
menopausal. Table I provides further information on the stage, 
grade, age and CA125 status of ovarian cancer patients.
Cell culture. SKOV3, and MDAH-2774 ovarian cancer cell lines 
(from American Type Culture Collection, USA), PEO1 (gift from 
Dr Helen Coley, University of Surrey) were cultured in RPMI 
phenol red-free complete media (Gibco) containing 10% fetal 
bovine serum (FBS), 5% penicillin/streptomycin (P/S) solution 
(5,000 µg/ml) and 5% Gibco 100X non-essential amino acids 
(NEAA) at 37˚C and 5% CO2. For cell treatments, cells were 
seeded overnight into 6-well plates with 2 ml complete media 
before media were aspirated and wells washed with PBS solution. 
The cells were incubated for 3 h in serum free media (phenol 
red-free media with 5% NEAA and 5% P/S, without FBS). The 
cells were then treated with vehicle (NS), oxytocin (OT) and/or 
cortisol (C) to make a final concentration of 100 nM. Cell concen-
tration and viability values were determined using a Countess™ 
automated cell counter based upon the method of trypan blue 
exclusion (Invitrogen, Paisley, Renfrewshire, UK), as previously 
described (32).
Wound healing assay. A solid line spanning the diameter of each 
well on a 6-well plate was drawn on the reverse side before cells 
were seeded at equal density and treated as stated above. The 
‘wound’ was created using a 200-µl yellow pipette tip (Fisher) 
and scratching a line through the cells which was perpendicular 
to the line drawn along the well. Images of each wound at 
0 hours (h), 6, 12 and 18 h after treatment were inspected by the 
Olympus IX71 Microscope and the images captured using the 
Photometrics Cool Snap™ CF camera. Percentage migration of 
cells into the wound after 18 h was calculated using the following 
formula: 1 - average width of wound at 18 h / average width of 
wound at 0 h*100.
RNA isolation, cDNA synthesis and quantitative RT-PCR. Total 
RNA was isolated using an RNA extraction kit (Sigma-Aldrich, 
UK), according to the manufacturer's instructions. RNA concen-
tration was determined by spectrophotometric analysis 
(NanoDrop; Thermo Scientific, UK) and agarose gel electropho-
resis. RNA (500 ng) was reverse-transcribed into cDNA using 
5 IU/µl RNase H reverse transcriptase (Invitrogen). Relative 
expression of the genes of interest was assessed by quantitative 
PCR (Q-PCR) on an ABI7400 instrument (Applied Biosystems) 
and xxpress® (BJS Biotechnologies) using SYBR® Green-PCR 
reaction mixture (Sigma-Aldrich) and the primers for GR, GAS5 
as previously described (33). For OTR the primers used were: 
(sense) 5'-TTACAATCACTA GGATGGCTACAA-3'; (anti-
sense) 5'-CATTTACATTCCCAC CAACAATTTAA-3'. As a 
negative control for all the reactions, distilled water was used in 
place of the cDNA. RNAs were assayed from two to three inde-
pendent biological replicates. The RNA levels were expressed as 
a ‘relative quantification’ using the housekeeping gene 18S RNA 
(RQ) value. ‘∆Ct method’ was employed for comparing relative 
expression results between treatments in Q-PCR (34).
Protein extraction from SKOV3, PEO1 and MDAH2774 
cells. Ovarian cancer cells were cultured to 80% confluence, 
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and in the presence or absence of OT, cortisol, cortisol and 
oxytocin (100 nM for 48 h). Cells were then lysed using 200 µl 
1X Laemmli buffer (Sigma-Aldrich) and denatured for 5 min 
at 100˚C before they were cooled on ice.
Western immunoblotting. Samples were separated on an 
SDS-10% polyacrylamide gel and the proteins were transferred 
to a nitrocellulose membrane. The membrane was blocked in 
TBS containing 5% dried milk powder (w/v) and 0.1% Tween-20, 
for 1 h at room temperature. After three washes with TBS-0.1% 
Tween-20, the nitrocellulose membranes were incubated with 
primary antibodies against caspase-3, Beclin-2 and GAPDH 
(Cell Signaling Technology). All primary antisera were used 
at a 1:1,000 dilution overnight at 4˚C. The membranes were 
washed thoroughly for 30 min with TBS-0.1% Tween, before 
incubation with the secondary HRP-conjugated immunoglob-
ulin (1:2,000) for 1 h at room temperature and further washing 
for 30 min with TBS-0.1% Tween-20. Antibody complexes 
were visualised as previously described (33).
Ovarian tissue microarray. Unstained paraffin tissue micro-
array slides containing multiple ovarian carcinoma and normal 
tissue micro-array (70 cases of ovarian carcinoma, 5 cases of 
tumour adjacent normal ovary and 5 normal ovarian tissue 
from different biopsies; Biomax USA) were used for this study.
The paraffin-embedded slides were deparaffinised and 
rehydrated by a series of washes in reducing concentrations of 
ethanol (100, 95, 70 and 50%) followed by rinsing in tap water 
for 10 min. Antigen retrieval was accomplished by incubating 
the slide in sodium citrate (pH 6.0) for 20 min in a microwave. 
Slides were washed in 0.4% of PBS-T for 5 min and then incu-
bated for 15 min in the PBS containing 0.3% H2O2 to stop the 
interference of the endogenous peroxidase activity. Blocking 
was carried out with 5% goat serum, followed by overnight 
incubation with primary GRα antibody. The following day, 
after several washes with PBS, slides were incubated with HRP 
conjugate-secondary antibody for 60 min. Further washing in 
PBS-T was carried out for 20 min before performing staining. 
Slides were then subjected to DAB staining, counterstained 
with haematoxylin and washed with 0.1% sodium bicarbonate. 
The extent of staining was scored based on the proportion 
of cells stained positive for GRα, as follows: 0, <5% of cells; 
1, 5-25% of cells; 2, 26-50% of cells; 3, 51-75%; and 4, >75% 
of cells. Scoring was calculated from the mean of the two 
independently conducted assessments.
GR luciferase reporter assay. SKOV-3 cells were incubated in 
12-well plates with McCoy's 5A medium supplemented with 
1.5 mM L-glutamine and 2.2 g/l sodium bicarbonate (Hyclone, 
Logan UT, USA (1 ml/well). The cells were co-transfected with 
1 µg of pGRE-Luc vector (a gift from Dr John A. Cidlowski, 
NIEHS) and 0.5 µg of the pRL-TK vector (Renilla luciferase, 
Promega, Madison, WI, USA) to correct for transfection 
efficiency in transfection media containing OptiMed and 
Lipofectamine 2000 (Invitrogen) as described previously (35). 
The transfection medium were replaced after 6 h with fresh 
culture medium containing 100 nM cortisol, 100 nM oxytocin, 
alone or in combination. The cells were grown overnight until 
90% confluent. Cell extracts were assayed using a dual-luciferase 
reporter assay system (Promega) following the manufac-
turer's instructions. Firefly and Renilla luciferase activities were 
measured for 10 sec each, respectively, using a CLARIOstar 
luminometer and the data were analyzed with Mars software 
(BMG Labtechnologies Inc., Durham, NC, USA). The relative 
luciferase activity level of each treatment (n=3) was expressed as 
the ratio of firefly/Renilla luciferase activity values.
In silico analysis of gene expression from microarray data. 
Oncomine (www.onocomine.org) is an online database 
consisting of previously published patient microarray 
data available to the public. We used this in silico dataset 
to compare the expression of OTR in normal and ovarian 
cancer tissues.
Statistical analysis. Statistical analysis was performed by the 
Student's t-test. A value of P<0.05 was regarded as statistically 
significant. For the immunohistochemistry studies, a Student's 
t-test where the assumptions of equal variances were not met, 
we used Levine's test, which uses often non-integer degrees of 
freedom. Q-PCR and western blot analysis data are reported 
as the mean ± SEM.
Results
Cortisol inhibits the anti-proliferative effects of OT in vitro. 
SKOV3, PEO1 and MDAH-2774 ovarian cancer cells were 
treated for 48 h with oxytocin (OT), cortisol (C), and cortisol 
plus oxytocin (C+OT) at 100 nM. This concentration was 
chosen in accordance with previous studies that demonstrated 
that 100 nM cortisol doses simulate stress conditions in vitro 
and this resembles physiological levels of circulating steroid 
in vivo (36). OT concentration was also chosen at 100 nM as 
it is the concentration at which the OTR was maximally acti-
vated in a number of in vitro studies (30). Staurosporine (ST) 
at 100 nM was also used as an extra control agent for reduc-
tion of cell proliferation (37). In SKOV3 and MDAH-2774 
cells, OT partially, but significantly, reversed the proliferative 
Table I. Patient details (age, stage, grade, CA125) recruited 
for this study.
Histology Grade Stage Age (years) CA125
Serous 3 IIIC 64   474
Serous 3 IIIC 48 4,350
Serous 3 IIIC 61   858
Serous 2 IIIC 54   537
Serous 3 IIIC 69   534
Serous 3 IV 65 UKN
Serous 3 IIIC 75   242
Serous 3 IIIC 65   478
Serous 3 IIIC 56 UKN
Serous 3 IIIC 64 2,657
Serous 3 IIIC 64   339
Serous 2 IIIC 56   542
UKN, unknown.
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effects of cortisol when compared to the effects of cortisol 
alone (Fig. 1A and C). In all three cell lines used, OT alone 
was able to significantly reduce the proliferation of ovarian 
cancer cells (Fig. 1). The extent of the inhibition varied, with 
OT having a more profound effect on PEO1 and SKOV3 cells.
Effects of cortisol and OT on cell migration. We then assessed 
the effects of C and OT on cell migration in scratch conditions. 
OT significantly reduced the migratory ability of SKOV3 
cells when compared to controls (Fig. 2A), whereas in PEO1 
cells, C alone induced a significant cell migration compared 
to controls and to OT treated cells (Fig. 2B). In MDAH2774, 
although the differences did not reach statistical significance, 
they followed a similar trend towards inhibition of cell migra-
tion by OT and induction by C (Fig. 2C).
Effects of cortisol and OT on apoptosis. To further understand 
the potential pro-apoptotic mechanisms of OT in vitro, we 
measured the levels of apoptosis-associated proteins in the 
presence or absence of cortisol.
After exposure to OT±C and C alone for 48 h, cleaved 
caspase-3 over total caspase-3 and Beclin-1 over GAPDH 
protein levels were examined by western blotting. Quantitative 
analysis of cleaved caspase-3 over total caspase-3 bands by 
scanning densitometry revealed a significant increase in this 
ratio in OT treated SKOV3 (56% P<0.01) and MDAH-2774 
(76% P<0.01) cells compared to cortisol alone (Fig. 3A and C). 
Surprisingly, in PEO1 cells, cortisol treatment induced more 
cleavage of caspase-3 when compared to OT (Fig. 3B). The 
effects of cortisol remained unaltered in the presence of 
oxytocin in all three cell lines, thus suggesting that there is no 
involvement of caspase-3 as a cross-talk mechanism in these 
models between C and OT.
We next measured the expression of the autophagy-related 
protein Beclin-1. Autophagy is a highly conserved cellular 
process that is involved in several catabolic processes, 
including degradation of long-lived proteins and organelles, 
and cell death (38). Although autophagy is initiated as a 
protective response to stress, the constitutive activation of 
Figure 1. Cell viability assay for control cells (NS), cells treated with 
100 nM oxytocin (OT), 100 nM oxytocin and 100 nM cortisol (OTC), 
100 nM cortisol (C) and 1 µM staurosporine (ST). (A) Viable cell count for 
SKOV3 cell lines treated for 48 h. (B) Viable cell count for MDAH-2774 cell 
lines treated for 48 h. (C) Viable cell count for PEO1 cell lines treated for 
48 h. Data are expressed as the mean ± SEM, *P<0.05, **P<0.01.
Figure 2. Wound healing assay for control cells (NS), cells treated for 48 h 
with oxytocin (OT) ± cortisol (OT+C, 100 nM) and cortisol (C, 100 nM) 
alone for SKOV3 (A), PEO1 (B) and MDAH-2774 (C). Data are expressed as 
the mean ± SEM, *P<0.05 to NS, ‡P<0.05 to OT.
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autophagy can lead to cell death by excessive self-degradation 
of essential cellular components (38,39). Beclin-1 protein levels 
were significantly increased in all three OT-treated cell lines 
when compared to cortisol alone or to cortisol and oxytocin 
(Fig. 3D-F). In all cell lines, OT appeared to reverse the reduc-
tion of Beclin-1 that was due to cortisol, since Beclin-1 levels 
were moderately elevated in SKOV3 and MDAH-2774 cells 
in cortisol and OT treated samples when compared to cortisol 
alone. Moreover, in PEO1, the induction of Beclin-1 was 
significant in the same preparations (Fig. 3E), thus suggesting 
that the effects of OT+C on cell proliferation described above 
may have been mediated by a potential cross-talk with mecha-
nisms regulating autophagy and subsequently cell death.
Expression of OTR, GRs and GAS5 in ovarian cancer 
patients. Quantitative RT-PCR revealed that GAS5 and all 
GR variants were expressed at the ovarian level (Fig. 4). No 
apparent differences in the expression of GRα, GRβ, or GRγ 
between control (n=10) and ovarian cancer (n=12) patients 
were found. However, GR-P was significantly upregulated in 
Figure 3. Expression of cleaved caspase-3 as a ratio of total caspase-3 and Beclin-1 in SKOV3 (A and D), PEO1 (B and E) and MDAH-2774 (C and F) cell lines 
treated for 48 h in NS, OT, OTC and C. Data are expressed as the mean ± SEM, *P<0.05, **P<0.01.
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ovarian cancer patients when compared to the control group 
(Fig. 4A). Moreover, the pseudo-GRE GAS5 was significantly 
downregulated in ovarian cancer (Fig. 4B), whereas OTR was 
significantly upregulated in the same cohort (Fig. 4C) when 
compared to controls. We also analysed the expression of gene 
copy number of OTR, using Oncomine datasets. OTR gene 
copy number showed an increased expression in the Bonome 
dataset in ovarian carcinoma patients (n=185) against normal 
ovarian surface epithelium (n=10; data not shown).
We then expanded on these observations at protein level 
using tissue microarray slides containing 70 samples of 
ovarian cancer and 10 samples of normal tissue. Results 
are presented as a percentage of total cells positive for GRα 
expression. The immunohistochemistry study shows 49% 
positive staining for GRα in the normal ovaries (n=10) and 
31% in malignant tissues [n=70; χ2 (1) = 1.28; P>0.5]. Of the 
malignant tissues, 31% of epithelial origin ovarian cancers 
were stained positive for GRα and 26% of germ cell cancers 
were positive for GRα.
In the sample 43.9% were at stage I, 21.1% stage II, 
28.1 stage III and 7% stage IV. Because of the relatively 
small sample and to increase statistical power, we grouped 
the patients in early stages (I and II) versus late (III and IV; 
Fig. 5A). After log transforming the GRα expression, the late 
stage patients had significantly higher expression of GRα (1.2) 
than early stage patients [0.4; t(54.3)=2.5; P=0.015]. There was 
no further correlation of GRα expression with clinico-patho-
logical features such as age and histological type of tumour.
Transactivation of GR by OTR and effects of OT and C on GR 
splicing in vitro. The effects of C and OT alone or in combina-
tion on transactivation of human GR were assessed using a 
GRE-luciferase reporter system in SKOV3 cells. Treatment of 
SKOV3 cells for 16 h with 100 nM OT did not induce any 
changes in the luciferase activity, whereas C alone exerted a 
significant increase. Interestingly, when SKOV3 cells were 
treated with C+OT, the increase in GRE activity was signifi-
cantly higher compared to the effects of C alone (Fig. 6). The 
effect was not additive.
OT drives differential splicing of GR isoforms in a cell-
specific manner. In SKOV3 (Fig. 7A) and PEO1 (Fig. 7B) cells, 
OT significantly induced GRβ expression, whereas only in 
PEO1, the expression of GR-P was significantly augmented. 
With regards to GAS5, it was induced in PEO1 (Fig. 7B) and 
MDAH-2774 cells (Fig. 7C).
Given the increase of OTR seen in the clinical samples, and 
since this may result from the cancer-induced stress responses 
as well, we tested the hypothesis that cortisol, a stress hormone, 
might affect OTR expression directly. SKOV3, PEO1 and 
MDAH-774 were treated for 48 h with cortisol, in an attempt 
to resemble a sustained moderate stress environment in vitro. 
When SKOV3, PEO1 and MDAH-774 cells were treated with 
cortisol (100 nM), the expression of OTR was significantly 
upregulated by 5-fold, 2-fold and in 81%, respectively, when 
compared to basal levels (data not shown).
Discussion
In this study, we provide to the best of our knowledge, for the 
first time, evidence for cross-talk between a stress hormone 
(cortisol) and a ‘social’ hormone (OT) at the molecular level in 
ovarian cancer cells. These findings have wider implications 
especially for ovarian cancer patients who frequently exhibit 
stress, depression, anxiety, and poorer overall quality of life 
(QOL) (40,41). A major finding of this study is the inhibitory 
role that oxytocin can exert over the cortisol effects in tumour 
cells. We demonstrate that OT reversed the effects of cortisol 
by inducing autophagy, as evident from the upregulation of 
Beclin-1. Interestingly, there is a correlation of decreased 
expression of Beclin-1 with poorer outcomes in patients with 
ovarian carcinoma (42); and between decreased expression of 
Beclin-1 with the development of epithelial ovarian tumours 
(43). This is of particular importance since synthetic gluco-
corticoids can promote cell survival in epithelial tumours, 
Figure 4. Gene expression of GR splice variants GRα, GRβ, GRγ, and 
GR-P (A), GAS5 (B) and oxytocin receptor (OTR) (C) in ovarian cancer (OC) 
patients (n=12) and control (n=10). Data are expressed as the mean ± SEM, 
**P<0.01 to controls.
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including breast and ovarian cancers. For example, cortisol 
can enhance the invasive potential of SKOV3 ovarian cancer 
cells (10). Moreover, to prevent chemotherapy-related side 
effects, dexamethasone is routinely administered to patients 
with ovarian cancer. In a recent clinical study, ovarian cancer 
patients receiving dexamethasone showed a significant 
induction of pro-cancer cell survival genes, including serum 
and glucocorticoid-regulated kinase 1 (SGK1) and map 
kinase phosphatase 1 (MKP1)/dual specificity phosphatase 1 
(DUSP1) at the tumour site. It appears therefore that gluco-
corticoids (GCs) may decrease chemotherapy effectiveness via 
induction of anti-apoptotic gene expression (44). In another 
study, dexamethasone not only induced therapy resistance of 
primary ovarian carcinomas in vivo, it also led to a faster basal 
growth of the xenografts (45). Collectively, these data suggest 
that while the anti-emetic effects by glucocorticoids may be of 
benefit to patients to tolerate the side effects of the treatment, 
their counteracting of cytotoxic treatments may minimize the 
treatment-induced growth retardation of ovarian cancer.
Furthermore, in the cell lines SKOV3 and MDAH-2774 
OT induced caspase-3, indicative of initiating apoptotic 
events. A similar effect has been observed in rat neuronal cells 
(46). However, the effects of cortisol on caspase-3 cleavage 
remained unaltered in the presence of oxytocin in all three 
cell lines, implying that OT exerts a direct apoptotic effect, 
Figure 5. Protein expression of GRα using tissue microarray. Positive staining for GRα as detected by stage (A). Immunohistochemical analysis of ovarian 
cancers expressing GRα in normal controls (B) and in patients with serous papillary carcinoma, presented as either early stage (C) or late stage (D).
Figure 6. Effects of 16-h treatment with 100 nM cortisol (Cort), 100 nM 
oxytocin (Oxyt) alone and in combination (C+O) on transactivation of 
human GR using a GRE-luciferase reporter system in SCOV3 cells. Bars 
represent means ± SEM, n=3. Different letters denote values significantly 
different from each other (P<0.01) analyzed by one-way ANOVA and Tukey 
post hoc test.
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involving a particular caspase, independent of cortisol. Over 
the past decade, a substantial amount of data implicates OT 
in proliferative and anti-proliferative effects in vitro, and here 
we have shown that OT can exert a cytostatic/cytotoxic effect 
in ovarian cancer cells. The OTR, is another ‘promiscuous’ 
GPCR in terms of its capacity to induce multiple signalling 
pathways involving PLC, cAMP, IP3, MAPK to name a few. 
Here we provide evidence for a unique cross-talk between OTR 
and GR, since OT can transactivate the GR gene when in the 
presence of cortisol. This can have implications in GR splicing 
events. For example, OT can compromise GR signalling by 
inducing multiple splicing isoforms (GRβ and GRγ) that can 
act in a dominant negative manner, including the induction of 
the pseudo-GRE GAS5.
Figure 7. Expression of the GR splice variants GRα, GRβ, GRγ, GR-P, and GAS5 following OT treatment (100 nm) in SKOV3 (A), PEO1 (B) and MDAH-2774 (C) 
cells. Data are expressed as the mean ± SEM, *P<0.05, ***P<0.01 to no supplement (NS).
Figure 8. Proposed model of the potential interactions between oxytocin (triangles) and cortisol (polygons) at concentrations mimicking high stress in vivo 
during ovarian cancer.
INTERNATIONAL JOURNAL OF ONCOLOGY 9
It is possible therefore for OT to act in a cell- or tissue-
specific manner and exert a dual role as a result. In the only 
in vivo study, intraperitoneal administration of OT resulted 
in the reduction of intraperitoneal dissemination of ovarian 
cancer cells followed by suppression of MMP2 and increases 
in expression of E-cadherin (30). Breastfeeding - a state where 
OT is markedly elevated for more than one year, reduces the 
risk of developing ovarian cancer compared with never breast-
feeding (47), and may also reduce endometrioid ovarian cancer 
risk to a greater extent than other subtypes (48,49). Our results 
are also in line with other studies showing anti-proliferative 
effects of OT in several, but not all, cancer cell types (26-28).
These data have wider implications in stress management 
for cancer patients. The severe emotional distress accom-
panying a diagnosis of cancer generally and ovarian cancer 
specifically and its initial treatment has been extensively docu-
mented (40). In ovarian cancer, social support has been related 
to higher NK cytotoxicity in PBMC and tumour-infiltrating 
lymphocytes (TIL), whereas distress was related to lower NK 
cytotoxicity in TIL (50). Ovarian cancer patients suffering 
from chronic stress, depression and low social support have 
increased MMP-9 levels in tumour-associated macrophages 
(51), of importance for tumour invasion and metastasis. 
Moreover, there is a substantial body of longitudinal research 
relating initial social support to lower morbidity and mortality 
from a variety of cancers (8). The results observed in the 
present study provide important evidence for possible mecha-
nisms linking social support to better cancer prognosis since 
social support is positively related to OT levels (52) and our 
results propose that OT may minimise the anti-apoptotic 
effects or stress-related cortisol in ovarian cancer.
The three ovarian cancer cell lines exhibit differences in 
GR expression levels but similarities in the response to OT 
(proliferation) and wound (mechanical scratch assay). SKOV3 
human ovarian clear cell adenocarcinoma cells were derived 
from the ascites of a Caucasian 64-year-old female. PEO1 is 
an adherent ovarian cancer cell line derived from a malig-
nant effusion from the peritoneal ascites of a patient with a 
poorly differentiated serous adenocarcinoma. MDAH-2774 
cells are of human ovarian endometrioid adenocarcinoma 
origin, isolated from the ascites of an untreated female 
patient. MDAH-2774 cells show a trend towards triploidy, 
particularly trisomy of chromosomes 1, 2, 3, 6, 11, 12, 16 and 
X and monosomy of chromosomes 17 and 21. SKOV3 have 
mutations in TP53 and PIK3CA genes, whereas MDAH2774 
have mutations in TP53, PIK3CA, KRAS, BRCA1 (silent) 
and BRCA2 (silent) (53). It should also be noted that there is 
heterogeneity in cultured cells and the SKOV3 cell line has 
been shown to contain cells with high and low invasive and 
migratory potential (54). This may provide an explanation of 
the variability seen in experiments involving SKOV3, PEO1 
and MDAH-2774 cell lines.
We have provided conclusive evidence that cortisol can 
induce OTR expression at concentrations that mimic a stressful 
milieu in vitro. This could be a compensatory defensive and 
regulatory response. In our study, there was also an induction 
of OTR in ovarian cancer patients compared to controls and, a 
slight decrease in GRα. We propose that OT may exert a dual 
beneficial effect: at the CNS level allowing patients to cope 
better with stress by seeking social support and by possibly 
feeling less lonely on one hand, and at the ovarian level by 
partially-reversing the deleterious effects of glucocorticoids on 
tumour cell viability, on the other; whilst retaining the useful 
anti-emetic effects of glucocorticoids (Fig. 8). However, this 
study did not include direct evidence linking these two levels 
in patients; including assessment of their psychosocial profile. 
Future studies need to examine prospectively the relationship 
between social support, systemic and in situ levels of OT and 
cortisol, and prognosis in ovarian cancer patients. This will 
enable to extend the observations found in this study and then 
point at possible clinical implications.
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